JP2022501336A5 - - Google Patents

Info

Publication number
JP2022501336A5
JP2022501336A5 JP2021514344A JP2021514344A JP2022501336A5 JP 2022501336 A5 JP2022501336 A5 JP 2022501336A5 JP 2021514344 A JP2021514344 A JP 2021514344A JP 2021514344 A JP2021514344 A JP 2021514344A JP 2022501336 A5 JP2022501336 A5 JP 2022501336A5
Authority
JP
Japan
Prior art keywords
polypeptide
optionally
phytosterols
seq
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514344A
Other languages
English (en)
Japanese (ja)
Other versions
JP7556848B2 (ja
JP2022501336A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051072 external-priority patent/WO2020056304A1/en
Publication of JP2022501336A publication Critical patent/JP2022501336A/ja
Publication of JP2022501336A5 publication Critical patent/JP2022501336A5/ja
Application granted granted Critical
Publication of JP7556848B2 publication Critical patent/JP7556848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514344A 2018-09-14 2019-09-13 mRNA治療薬を使用したがんを治療するための方法及び組成物 Active JP7556848B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862731335P 2018-09-14 2018-09-14
US62/731,335 2018-09-14
US201862770024P 2018-11-20 2018-11-20
US62/770,024 2018-11-20
US201962881322P 2019-07-31 2019-07-31
US62/881,322 2019-07-31
PCT/US2019/051072 WO2020056304A1 (en) 2018-09-14 2019-09-13 Methods and compositions for treating cancer using mrna therapeutics

Publications (3)

Publication Number Publication Date
JP2022501336A JP2022501336A (ja) 2022-01-06
JP2022501336A5 true JP2022501336A5 (cg-RX-API-DMAC7.html) 2022-09-20
JP7556848B2 JP7556848B2 (ja) 2024-09-26

Family

ID=68104746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514344A Active JP7556848B2 (ja) 2018-09-14 2019-09-13 mRNA治療薬を使用したがんを治療するための方法及び組成物

Country Status (7)

Country Link
US (1) US20230081530A1 (cg-RX-API-DMAC7.html)
EP (1) EP3849589A1 (cg-RX-API-DMAC7.html)
JP (1) JP7556848B2 (cg-RX-API-DMAC7.html)
CN (1) CN113015540A (cg-RX-API-DMAC7.html)
AU (1) AU2019338535A1 (cg-RX-API-DMAC7.html)
CA (1) CA3112781A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020056304A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CA3149386A1 (en) * 2019-07-31 2021-02-04 Modernatx, Inc. Compositions and methods for delivery of rna interference agents to immune cells
AU2021270587A1 (en) * 2020-05-14 2022-12-08 Modernatx, Inc. LNP compositions comprising an mRNA therapeutic and an effector molecule
CA3178965A1 (en) 2020-05-15 2021-11-18 Christian COBAUGH Messenger rna encoding cas9 for use in genome-editing systems
WO2022010764A1 (en) * 2020-07-06 2022-01-13 Vivtex Corporation Mucopenetrating formulations
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
WO2022120560A1 (zh) * 2020-12-08 2022-06-16 深圳市瑞吉生物科技有限公司 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用
CA3216873A1 (en) * 2021-04-17 2022-10-22 Intellia Therapeutics, Inc. Lipid nanoparticle compositions
CN116406426A (zh) * 2021-04-29 2023-07-07 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
WO2022240960A1 (en) 2021-05-14 2022-11-17 Crispr Therapeutics Ag Mrna large scale synthesis and purification
US12251471B2 (en) * 2021-07-26 2025-03-18 Oregon State University Inhalable therapeutics
CN114457054A (zh) * 2022-02-24 2022-05-10 中国科学技术大学 一种cGAS mRNA的制备及作为免疫激活剂的应用
WO2023192503A1 (en) * 2022-03-30 2023-10-05 The Johns Hopkins University Compositions of lipid nanoparticles for plasmid dna delivery to the liver and methods for preparing the same
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2023246840A1 (en) * 2022-06-22 2023-12-28 Wuhan Houxian Biopharmaceutical Co. Ltd. Combination of il-12 and ox40l for cancer immunotherapy
CN119894525A (zh) * 2022-07-15 2025-04-25 哈佛大学校长及研究员协会 Mucispirillum组合物及其癌症治疗方法
US20250387486A1 (en) * 2022-08-09 2025-12-25 Stemirna Therapeutics Co., Ltd. Lipid composition
CN115869332A (zh) * 2022-10-27 2023-03-31 北京新合睿恩生物医疗科技有限公司 递送至体内后在肝脏少表达的mRNA药物及其制备方法
EP4649087A2 (en) 2023-01-11 2025-11-19 Engage Biologics Inc. Non-viral expression systems and methods of use thereof
EP4470559A1 (en) * 2023-06-02 2024-12-04 Imgen-T-Srl Combination containing an mrna vaccine and an immune modulating mrna for improved immunogenicity and efficacy
WO2025098508A1 (zh) * 2023-11-10 2025-05-15 贝达药业股份有限公司 标记性多肽、治疗剂及其应用
US20250177432A1 (en) * 2023-12-04 2025-06-05 Wuhan Houxian Biopharmaceutical Co. Ltd. Rna molecules and compositions for cancer immunotherapy
WO2026044248A1 (en) * 2024-08-23 2026-02-26 Akagera Medicines, Inc. Ionizable cationic lipids and lipid nanoparticle compositions
WO2026078565A1 (en) 2024-10-10 2026-04-16 Crispr Therapeutics Ag Messenger rna encoding cas9 for use in genome-editing systems

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2428570B1 (en) 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP2173378B1 (en) * 2007-06-27 2014-03-19 Admune Therapeutics LLC Complexes of il-15 and il-15ralpha and uses thereof
DK2205618T3 (en) 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
EP3434774A1 (en) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
SG11201702295UA (en) 2014-09-22 2017-04-27 Intrexon Corp Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
AU2016251687C1 (en) * 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
SMT202200310T1 (it) * 2015-12-23 2022-09-14 Modernatx Inc Metodi di utilizzo dei polinucleotidi codificanti il ligando di ox40
RS63625B1 (sr) * 2016-05-18 2022-10-31 Modernatx Inc Kombinacije irnk koje kodiraju imunomodulirajuće polipeptide i njihova upotreba
CA3024509A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
PL3458083T3 (pl) * 2016-05-18 2023-03-13 Modernatx, Inc. Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
CN110267978A (zh) 2016-10-07 2019-09-20 得克萨斯大学体系董事会 用于治疗癌症的表达膜锚定的il-12的t细胞
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
US20190314291A1 (en) 2018-01-30 2019-10-17 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells

Similar Documents

Publication Publication Date Title
Liu et al. Advances in immunotherapy for triple-negative breast cancer
US8367628B2 (en) Amphoteric liposome formulation
JP2020520640A5 (cg-RX-API-DMAC7.html)
JP2023552195A5 (cg-RX-API-DMAC7.html)
CN104903450A (zh) 寡核苷酸癌症疗法的给药和施用
JP5623016B2 (ja) 癌治療法およびそれに用いる医薬組成物
EP3603748A1 (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
JP2020111589A (ja) リポソーム製剤
Fan et al. Lipid-based nanoparticles for cancer immunotherapy
JP2022188159A (ja) 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
CN104884637A (zh) 利用生物标志物通过bcl2表达的调节治疗癌症的方法
CN108310378A (zh) 一类新型免疫联体抗肿瘤创新药物的制备及其应用
JP2022525223A (ja) sEphB4-HSA融合タンパク質を用いたがんの治療
KR20240158980A (ko) 유기 화합물
TW202114647A (zh) 用於治療具有高間質壓力的腫瘤受試者的癌症的小分子抑制劑
EP4031873A1 (en) Quantitative spatial profiling for lag-3 antagonist therapy
TWI760319B (zh) 乳癌治療
WO2023161378A1 (en) Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof
WO2009051712A1 (en) Dnai amphoteric liposome formulation
US20260000757A1 (en) Combination therapy for lung cancer
WO2007065017A2 (en) Oligonucleotide cationic liposomal delivery system
WO2020160409A1 (en) Methods of treating cancer using a combination of tumor membrane vesicles and metformin
WO2022097634A1 (ja) 血管新生依存性疾患治療に使用される医薬用組成物
CN116621966B (zh) 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用
Le et al. Therapeutic Management of Lymphoma: Conventional Strategies and Overcoming Treatment Barriers with Nanotherapeutics